Amgen/Takeda ASCO Data Could Help Guide Vectibix Use In mCRC
The PARADIGM study took place in Japan, but it was described as the first to prospectively evaluate treatment of wild-type RAS mCRC and left-sided primary tumors.
You may also be interested in...
First quarter revenue of $6.2bn and product sales of $5.7bn were up 6% and 2%, respectively, year over year. However, a looming – and potentially growing – tax liability is a multibillion-dollar overhang.
Can-Fite’s A3AR agonist was inferior to Amgen’s Otezla by most efficacy measures, while Bristol Myers Squibb’s competing deucravacitinib is closer to approval and did beat Otezla.
The Swiss biotech says the ERADICATE trial shows areas of differentiation for the antibiotic, like utility in pneumonia and across gram-negative and gram-positive bacteria.